General Eye Care
Age-related macular degeneration (ARMD) is a progressive disease of the retina that causes blurring of your central. The blurring happens because of damage to the macula, a small area at the back of the eye. The macula helps you see the fine detail in things that your eyes are focusing on. Macular degeneration makes it harder to do things that require sharp central vision, like reading, driving, and recognizing faces. It does not affect side vision, so it does not lead to complete blindness. The disease is thought to be caused by a combination of genetic and environmental factors, and it is most common in people who are age sixty and over. ARMD is the leading cause of visual impairment in senior citizens. An estimated fifteen million people in the United States have it, and approximately two million new cases are diagnosed annually.
There are two types of macular degeneration-wet and dry. The dry form is by far the most common type. The wet form is much less common, but it happens more quickly and is more severe.
- Dry ARMD accounts for about 9 out of 10 cases of macular degeneration. It develops slowly and causes central vision to become dimmer or more blurry over time. It usually does not cause severe vision loss unless it turns into the wet form.
- Wet ARMD accounts for only about 1 out of 10 cases of macular degeneration. It can cause serious vision loss within months or even weeks. People who have the wet form have the dry form first.
You may have either type in just one eye, but over time you may get it in the other eye too.
If you have the wet form of macular degeneration, you may have one or more of the following treatments:
- Photodynamic therapy
- Injections of medicine into your eye
- Laser surgery
These treatments can’t restore central vision, but they may slow down vision loss. If your doctor recommends photodynamic therapy, injections, or laser surgery, it is important to have it done right away.
No one has found a treatment or a cure for the dry form of age-related macular degeneration. Antioxidants may protect against age-related macular degeneration by preventing free radicals or unstable oxygen from damaging the retina. Your ophthalmologist at Advanced Vision Institute will direct you in the appropriate course of treatment for your specific needs.
Eylea, Avastin and Lucentis for Macular Degeneration
Recently, the FDA has approved Eylea for the treatment of the wet form of ARMD (age related macular degeneration), the leading cause of blindness in the elderly. Eylea works by inhibiting unwanted blood vessel growth in the retina. The blood vessels have the potential to leak, causing damage to the retina. The generic name for Eylea is Aflibercept.
Eylea is the third AMD drug to be approved by the FDA. Macugen inhibits a single form of VEGF, while Lucentis, like Eylea, blocks all forms. All three of these prescriptions are administered by injection. Lucentis is usually given once a month, although some patients may need treatment less frequently. Macugen is given every six weeks. Eylea is given once every two months after three once-a-month injections.
Lucentis, is currently the preferred drug treatment for AMD nationwide. Since Lucentis is a lower dose form of Avastin, some doctors prefer to treat patients with a diluted formulation of Avastin itself. The doctors at Advanced Vision Institute will assess your individual case, and help you to decide which treatment best suits your needs.